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Coronary heart diseaseBackground: Exercise-based cardiac rehabilitation (CR) has long been a cornerstone in the secondary pre-
vention of coronary heart disease (CHD). Despite meta-analyses of randomised trials demonstrating a
positive impact of CR on cardiovascular mortality, hospitalisation, exercise capacity and health related
quality of life, the impact of CR on all-cause mortality remains uncertain, especially in the context of con-
temporary clinical practice. This CR meta-analysis of trials in patients with coronary heart disease using
individual participant data (IPD) (CaReMATCH) seeks to (1) provide definitive estimates of the effective-
ness of CR in terms of all-cause mortality, cardiovascular mortality, hospitalisation and health-related
quality of life, and (2) determine the influence of individual patient characteristics (e.g. age, sex, risk fac-
tors) on the effectiveness of CR to inform a personalised CR-approach.
Methods: Randomised controlled trials will be identified that were performed in the last decade, to
ensure that CR was performed in combination with contemporary medical care (2010–2020). For our first
aim, outcomes of interest include all cause- and CVD-related mortality and hospitalisations. To answer
our second research question, we will collect data on exercise capacity, health-related quality of life,
and patient baseline demographic and clinical data. Original IPD will be requested from the authors of
all eligible trials; we will check original data and compile a master dataset. IPD meta-analyses will be
conducted using a one-step meta-analysis approach where the IPD from all studies are modelled simul-
taneously whilst accounting for the clustering of participants within studies.
Discussion: Findings from CaReMATCH will inform future (inter)national clinical and policy decision-
making on the (personalised) application of exercise-based CR for patients with CHD.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular diseases (CVDs), including coronary heart dis-
ease (CHD), are a leading cause of global mortality and morbidity,
responsible for approximately one third of total deaths and 20% of
the worldwide disease burden [1]. Reducing physical inactivity and
sedentary behaviour are potent, well advocated, non-
pharmacological, primary and secondary preventative strategies
for CHD [2–4]. Although there is a lack of global consensus on exer-
cise mode and intensity for cardiac rehabilitation (CR), the applica-
tion of CR promotes secondary prevention of CVD and is an
essential component of routine care for cardiac patients [5,6].Exercise-based CR is recommended (with the highest level of sci-
entific evidence - class I) by the European Society of Cardiology
(ESC) [7], the American Heart Association (AHA) and the American
College of Cardiology (ACC) [8]. Core components of exercise-based
CR include patient assessment, physical activity counselling, exer-
cise programme, nutrition counselling, weight management, lipid
management, blood pressure management, smoking cessation
and psychological support [7].
These global recommendations for CR are supported by studies
that find CR-related improvements in exercise capacity, health-
related quality of life, and reductions in hospital admissions
[9,10,11]. Findings related to mortality, however, are less ubiqui-
tous. In contrast to early Cochrane meta-analyses [9,10], the most
recent Cochrane review [11], did not observe a statistically signif-
icant reduction in all-cause mortality following exercise-based CR
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mortality in the most recent meta-analysis may be due to
improved medical management of CVD in recent years. Another
possible explanation may be the heterogeneity of the CHD popula-
tions included in most recent studies. Moreover, randomized con-
trolled trials (RCT) to date have lacked representation of the
elderly, females, and those from low socio-economic backgrounds
[10],[12]. Therefore, substantial differences in individual patient
responses to CR may be present, and it is unknown whether the
benefits of CR are moderated by participant characteristics. Better
insight into these topics may clarify the impact of CR on all-cause
mortality and contribute to a personalised approach of CR for indi-
vidual patients with CHD.
By performing a CR meta-analysis on patients with coronary
heart disease using individual-participant data (IPD) (CaRe-
MATCH), it is possible to provide definitive estimates on outcomes
of CR (mortality, hospitalisation, exercise capacity, health-related
quality of life) with higher power compared to individual RCTs.
Thereby, the higher sample size of the pooled IPD provides the
ability to study underlying mediators of an effect on CR outcomes.
Improved insight into whether patient or exercise (e.g. fitness,
amount, type, or location of exercise) characteristics affect all-
cause mortality or hospitalisation following CR, will ultimately
enhance the benefits of CR.
CaReMATCH is an international collaboration with the goal of
undertaking IPD meta-analysis of RCTs that investigate the impact
of CR in CHD based on a systematic review of contemporary RCT
evidence. The information gained from the CaReMATCH project
will help inform future (inter)national clinical and policy
decision-making on the use of exercise-based CR in CHD. The pri-
mary objectives of the CaReMATCH IPD meta-analysis is to:
1. Provide definitive estimates of the effectiveness of CR in CHD
versus control on all-cause mortality, cardiovascular mortality,
hospitalisation and health-related quality of life.
2. Analyse the influence of pre-randomisation patient characteris-
tics on the effectiveness of CR in CHD, including age, sex, diag-
nosis (post-myocardial infarction only, revascularisation only,
angina only, mixed CHD population) and exercise capacity.
3. Perform an exploratory analysis to assess whether the change in
exercise capacity mediates the effectiveness of the CR on all-
cause mortality, hospitalisation and health-related quality of
life.
4. Perform an exploratory analysis to assess the importance of fac-
tors on effectiveness of CR in CHD, including the amount of
exercise prescribed, the setting in which exercise is undertaken
(centre versus home), and the provision of additional interven-
tional elements such as psychological or educational support.
2. Methods
2.1. Search methods for identification of studies
Trials for inclusion in the CaReMATCH project were identified
from the 2016 Cochrane review plus any eligible trials published
since Anderson et al. [11], identified through a systematic search.
In total, 63 Randomised controlled trials (RCTs) were included in
the latest update of the CR Cochrane reviews. To reflect contempo-
rary CHD medical management, this project will focus on the IPD
from trials in CHD patients published since 2010. Specific rationale
for 2010 cut-off included (1) digitisation of healthcare resulting in
potential improvements in quality, efficiency, and population
health [14], (2) in 1998/2000 the American Heart Association set
a decade-long goal to reduce CHD and stroke risk by 25% by
2010, which was realised [15], and (3) publications from 2010
onwards include data predating 2010, thus this cut-off ensuresincluded data is at least within the last 20 years. For the updated
systematic search, the 2016 Cochrane search was reproduced with
time period included from July 2014 onwards. The following data-
bases were searched CENTRAL (Cochrane Central Register of Con-
trolled Trials), DARE (Database of Abstracts of Reviews of Effects),
HTA (Health Technology Assessment), MEDLINE and Medline in
Process (Ovid), EMBASE (Ovid), and CINAHL (Cumulative Index to
Nursing and Allied Health Literature) Plus (EBSCO).
Data from each RCT will be sought including (1) individual
patient characteristics: age, sex, socio-economic status (employ-
ment and education level proxies), medication use, CVD risk fac-
tors, disease type, and exercise capacity; (2) individual outcomes
of all-cause mortality, CV mortality, hospitalisations, myocardial
infarction, revascularization, and health-related quality of life
(HRQoL); and (3) CR characteristics: duration, single versus
multi-component interventions, mode, and intensity (e.g. % of
maximum heart rate, rating of perceived exertion).2.2. Eligibility criteria for studies
We will include studies if they meet the following inclusion and
exclusion criteria:
 Study design: RCTs with a minimum follow-up of 6 months. We
excluded studies with a non-randomised allocation.
 Population: Patients with the diagnosis of a myocardial infarc-
tion, who had undergone revascularization (coronary artery
bypass grafting [CABG]) or percutaneous coronary intervention
(PCI) or who have angina pectoris or CHD defined by
angiography.
 Context: Patients managed in any setting i.e. hospital, commu-
nity facility or home.
 Intervention: Exercise-based CR was defined as a supervised or
unsupervised inpatient, outpatient, community-based, or
home-based intervention that included some form of exercise
training, either alone or in addition to psychosocial and/or edu-
cational interventions.
 Comparator: The comparator could include standard medical
care and psychosocial and/or educational interventions, but
not any structured exercise training.
 Sample size: No restrictions on sample size were enforced to
maximise available data.
Table 1 lists the characteristics of the [n = 8] studies included
from the Cochrane 2016 review. As of July 2020, one investigator
declined to provide data as the data was no longer available [20].
An updated Cochrane review [11], is currently ongoing [Led by
RST], and any new randomised trials identified will inform this
IPD meta-analysis.2.3. Main outcomes
In accordance with the study research objectives we will seek
IPD for the following outcomes from eligible trials:
– Mortality (all-cause, death due to CVD): incidence and time-to-
event;
– Hospital admission/re-admission (all-cause, CVD specific): inci-
dence and time-to-event;
– Disease specific health-related quality of life: outcome at base-
line (pre-randomisation) and several post-randomisation
follow-up time points; and
– Exercise capacity as a mediator (irrespective of assessment
method): outcomes at baseline and at several post-
randomisation follow-up time points.
Table 1
Characteristics of the [n = 8] studies included from the Cochrane 2016 review.
First
author
(year)
N = patients1 Trial
location
and site
Mean
age
Male
(%)
CHD Diagnosis2 Intervention/
Exercise type
Overall
CR
duration
(weeks)
Exercise
frequency
(sessions/
week)
Mean
session
duration
(minutes)
Overall
exercise
duration
(minutes)
Exercise
setting3
Longest
follow-up
(months)
Aronov
(2010)
392 Russia
Multicentre
52 94% Mixed Aerobic 52 3 45–60 8190 Centre 12
Houle
(2012)
65 Canada
Single
centre
59 78% Mixed Aerobic
(pedometer
based
increased
stimulation
of physical
activity)
52 NA NA NA Home 12
Maddison
(2015)
170 New
Zealand
Multicentre
60 81% Mixed Aerobic
(mobile
phone
intervention
to stimulate
physical
activity)
24 NA NA NA Home 6
(24 weeks)
Mutwalli
(2012)
49 Saudi
Arabia
Single
centre
57 100% Revascularisation
(CABG)
Aerobic
(walking
program)
NR NR NR NR Home 6
Oerkild
(2012)
40 Denmark
Single
centre
77 58% Mixed Aerobic 6 6 45 1620 Centre 54
Reid
(2012)
223 Canada
Multicentre
56 84% Mixed Aerobic
(internet-
based
stimulation
to increase
physical
activity)
NA NA NA NA Home 12
Wang
(2012)
160 China
Multicentre
58 76% Post-myocardial
infarction
Aerobic 6 NR NR NR Home 6
West
(2012)
1813 United
Kingdom
Multicentre
64 74% Post-myocardial
infarction
Aerobic 6–8 1–2 1200 Centre 84–108
(7–
9 years)
NA, not applicable; NR, not reported.
1 Total number of participants randomised.
2 Post-mycardial infarction only, revascularisation only, angina only or mixed CHD population.
3 The delivery setting of cardiac rehabilitation; home, centre or both.
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methods, standardisation procedures will be decided once all of
the available data has been collected.
2.4. Collection of data
2.4.1. Investigator contact
Wewill initially email all trial investigative teams via the corre-
sponding author as detailed in publications to tell them about our
IPD meta-analysis, and to ask if they are willing to share their orig-
inal IPD. As part of the review process we have previously been in
contact with a number of investigators for the purpose of obtaining
data and have received positive responses from several contact
authors.
Members of this IPD meta-analysis project group have links
with the majority of study investigators, so if we fail to receive a
positive response to our initial email invitation, individual mem-
bers of the project group will be assigned to make further contact
by email or telephone. Study investigators still not responding or
unwilling to contribute their study data will be sent a final note
inquiring why they are unable to participate.
2.4.2. Data format
The procedure for collection and collation of data will be coor-
dinated by the project lead [BB] based at the Liverpool Centre for
Cardiovascular Science, University of Liverpool. Participating studyauthors will be asked to provide anonymised primary datasets cor-
responding to minimum data required to answer the primary
research objectives. Where possible, electronic versions of datasets
will be sought, together with written details of the coding of the
variables. We will accept databases in all formats in order to min-
imise the amount of work for primary study authors; however, ide-
ally the format will be a two-dimensional spreadsheet with one
subject per row and variables listed by column.
2.4.3. Data transfer and storage
Methods of receiving raw data from investigators may vary
depending on the security concerns of their host institutions. How-
ever, we anticipate that in most cases data transfer will be via an
encrypted data file sent by email to the project lead [BB] or via
the Liverpool Centre for Cardiovascular Science password-
protected drop box facility. Once received, data will be stored in
a secure computer server managed by the Executive Management
Group. Each raw data set will be saved in its original format and
then converted and combined into one overall dataset with stan-
dardised variables. We will work with individual trial authors to
ensure standardisation of variables.
2.4.4. Data checking
We will: (1) evaluate data from each study and compare these
with the available publication(s); (2) check each dataset for the
range of included variables to make sure all values are reasonable;
4 B.J.R. Buckley et al. / IJC Heart & Vasculature 30 (2020) 100616(3) assess missing observations for each variable and check against
the original publication; (4) attempt to replicate results reported in
the original publication, including baseline characteristics and out-
come data at each available follow-up period, by reproducing the
statistical methods as reported by the study authors; (5) discuss
and clarify any discrepancies or missing information between our
results and those presented in each original publication with the
original study authors.
Once data checks are complete and satisfactory, individual
study datasets will be combined to form a newmaster dataset with
a variable added to indicate the original study. Copies of the master
data set will be held by the project statistician [RST]. Data from
individual datasets will remain the property of the individual col-
laborators who have provided IPD.2.5. Statistical analysis
Due to the complexity of the statistical analyses, the following
section represents the planned principal analyses. A detailed statis-
tical analysis plan will however be produced prior to any analyses
being conducted. Analyses will be aligned to the latest guidance
from the Cochrane Prospective Meta-Analysis Methods Group,
existing recommendations for IPD meta-analyses [16], and under-
pinned by a previous IPD meta-analysis protocol [19].2.5.1. Descriptive analysis
Both study and patient-level characteristics of included RCTs
will be presented. We will also compare study-level and patient-
level characteristics between the included studies and studies that
were eligible but did not supply IPD, to determine if the included
IPD studies are a representative (unbiased) sample of all eligible
studies.2.5.2. IPD meta-analysis
IPD will first be analysed comparing CR versus control in each
separate study independently via linear regression models for con-
tinuous responses such as HRQoL, and Cox regressions for time to
event data such as mortality. Individual trial data sets will then be
combined, and a one-stage meta-analysis undertaken to compare
CR and control. Appropriate regression models (linear, logistic,
Cox) will be used, with a fixed effect on individual study and
patient-level covariates, as well as a comparison of models with
a fixed effect on intervention and random effects on intervention
across trials. Continuous outcomes will be analysed with adjust-
ments for baseline values. Heterogeneity will be assessed using
the I2 statistic.
If original data sets are not available for some RCTs, we will use
methods to combine IPD with aggregate data where appropriate.
The benefit of using aggregate data is to prevent bias due to lack
of response of the lead author of a paper. For example, authors
who are unwilling to provide access to datasets may be willing
to run analyses to provide the necessary estimates for a ‘two stage’
analysis, or such data may be available from primary publications.2.5.3. Subgroup and mediation analysis
Any modification of CR versus control effects across pre-defined
patient subgroups (i.e., age, sex, socio-economic group, ethnicity,
CHD aetiology, CHD risk factors, and exercise capacity), exercise
programme duration, and trial geographical locality will be
assessed by examining the significance of the subgroup by CR/con-
trol group interaction term within the model. Where available, the
importance of the amount of exercise will be assessed by fitting the
prescribed exercise duration as a continuous variable and examin-
ing the interaction with intervention.Mediation analysis will be conducted to examine the associa-
tion between changes in exercise capacity and health-related qual-
ity of life and clinical events [17].
2.5.4. Publication bias
Following published guidance, we will assess publication bias in
this IPD meta-analysis in several ways [18]:
– Assess funnel plot asymmetry with and without studies using
IPD.
– When IPD cannot be obtained, the impact on meta-analysis con-
clusions will be investigated by including the aggregate data
from the studies lacking IPD.
– Where the inclusion of studies lacking IPD seem to have an
important statistical or clinical impact, we will compare the
characteristics of the studies with IPD and those without to
see if there are key differences (e.g. quality, length of follow
up, statistical methods).
2.6. Project management and ethics
The ‘CaReMATCH Executive Management Group’ refers to the
core team of researchers who will oversee the strategic direction
of the protocol; the ‘CaReMATCH Collaborators’ refers to those
linked to the project such as trial teams who provide data sets
for the study. Members of the Project Executive Management and
Collaborative groups are listed at the end of this protocol.
2.6.1. CaReMATCH executive management group
The roles of the CaReMATCH Executive Management Group are
to:
– Agree the research questions addressed by the collaboration
and develop the initial protocol;
– Agree the data collection proforma;
– Oversee arrangements for secure data handling;
– Review the publication strategy for the collaboration; and
– Ensure that data are only used, and any additional research (in-
cluding updating of the combined data sets with emerging evi-
dence) only proceeds, following consultation and agreement
with the Collaborative Group.
2.6.2. CaReMATCH collaborative group
The Executive Management Group will act as a liaison between
members of the Collaborative Group. The Collaborative Group will
be composed of a representative from each of the included trials.
We will invite new collaborators as new eligible studies are com-
pleted. Members of the collaborative group will be given opportu-
nities to participate in decision making regarding the study design
and analyses. We intend members of the collaborative group to
have opportunities to network and identify future CaReMATCH
research questions suitable for analysis with the IPD dataset. Once
the Collaborative Group and initial dataset are established, we will
develop mechanisms for communication and input on method-
ological issues.
2.6.3. Data ownership and confidentiality
Participants in the individual trials have previously consented
to participation in their respective trial. Given that the analyses
proposed are simply an extension of the core analysis of the con-
stituent trials, we do not anticipate that additional ethical permis-
sion will be required. We will ensure that datasets shared as part of
the project include no patient identifiable information (such as
names and addresses), that all data storage is in accordance with
the regulations governing research at the Liverpool Centre for Car-
diovascular Science, University of Liverpool, and will obtain a
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dures for the transmission, storage, analysis and dissemination.
The collaborators remain the custodians of their own data and
retain the right to withdraw their data from the analysis at any
time.
2.6.4. Publication policy
Requirements for authorship will follow those of the Interna-
tional Committee of Medical Journal Editors (http://www.icmje.
org). A primary publication of the results of this review will be pre-
pared by the Executive Management Group. This and all other CaR-
eMATCH manuscript drafts will be circulated to the Collaborative
Group for comment, revision and approval.
3. Discussion
CaReMATCHwill establish a collaborative group and conduct an
IPD meta-analysis of randomised controlled trials of exercise-
based CR in CHD patients, focusing on studies that were published
between 2010 and 2020 to understand the role of CR in contempo-
rary medicine. A primary strength of an IPD approach is the ability
to investigate treatment modifiers. Project findings will therefore
provide clinicians and healthcare policy makers with definitive
estimates and corresponding guidance on differential responses
to CR across different CHD patient subgroups. This will improve
understanding of the role of CR, including the role of personal char-
acteristics in contemporary medicine.
CaReMATCH Executive Management Group
All authors are members of the CaReMATCH Executive Manage-
ment Group.
CaReMATCH Collaborator Group (as of July 2020; pending 2020
Cochrane CR review update)
Ralph Maddison, National Institute for Health Innovation,
University of Auckland, Auckland, New Zealand
David Aronov, State Research Center for Preventive Medicine.
Petroverigsky, Moscow
Julie Houle, Nursing Department, Université du Québec à Trois-
Rivières, Trois-Rivières City, Québec, Canada.
Funding. The authors have no funding to declare.
Registration. PROSPERO registration is being completed in parallel
with this protocol.
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